๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Tianjin
Clinical trial register · China

Clinical Trials in Tianjin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Tianjin 6 Beijing 6 Wuhan 3 Nanjing 2 Xuzhou 2
Narrow the registerReset
Recruitment status
Phase
Site location
Tianjin6 Beijing6 Wuhan3 Nanjing2 Xuzhou2
All 14 locations
Target enrolment
to

Trials with a site in Tianjin

6 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
NCT07585760Multiple Myeloma (MM), Multiple Myeloma Light Chain Induced Renal Insufficiency
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
26
Tianjin
2026-09-10
Not yet open
HP-001 Plus Dexamethasone for Relapsed/Refractory Multiple Myeloma With Extramedullary Disease
NCT07811986Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2
20
Tianjin
2026-09-01
Not yet open
Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification
NCT07687004Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2
50
Tianjin
2026-08-01
Not yet open
A Clinical Study to Evaluate the Safety and Preliminary Efficacy of QI-019B in Patients With Relapsed/Refractory Multiple Myeloma.
NCT07539233Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
24
Tianjin
2026-04-15
Not yet open
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผˆLB2505-0001๏ผ‰
NCT07399444Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase EARLY_PHASE1
38
Zhengzhou, Wuhan, Xuzhou, Nanchang, Beijing, Tianjin
2026-01-10
Not yet open
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
NCT07181239Multiple Myeloma (MM)
Keymed Biosciences Co.Ltd
Phase 3
280
Tianjin
2025-09
Rows per page Showing 1–6 of 6
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 27 September 2026. https://priyalifescience.com/clinical-trials-china/city/tianjin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 6 of those studies with a site in Tianjin that also match the filters currently applied.

How many clinical trials are recruiting in Tianjin?

1 of the 6 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 5 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Tianjin), 6 studies
PhaseStudiesRecruitingShare
Phase 22133.3%
Phase EARLY_PHASE12033.3%
Phase 1/21016.7%
Phase 31016.7%

Most active sponsors

Lead sponsors with the most studies (Tianjin)
Lead sponsorStudiesRecruiting
Institute of Hematology & Blood Diseases Hospital, China51
Keymed Biosciences Co.Ltd10
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.